Zai Lab - ZLAB Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZLAB shares.
View ZLAB analyst ratings or view top-rated stocks.

5 Wall Street analysts have issued 1 year price targets for Zai Lab's stock. Their ZLAB share price forecasts range from $64.00 to $199.00. On average, they expect the company's stock price to reach $119.00 in the next year. This suggests a possible upside of 205.8% from the stock's current price.
View analysts price targets for ZLAB or view top-rated stocks among Wall Street analysts.

Zai Lab's stock was trading at $62.85 at the start of the year. Since then, ZLAB shares have decreased by 38.1% and is now trading at $38.92.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our ZLAB earnings forecast.

Zai Lab Limited (NASDAQ:ZLAB) announced its quarterly earnings results on Tuesday, August, 9th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.95) by $0.49. The business had revenue of $48.18 million for the quarter, compared to analyst estimates of $46.78 million. Zai Lab had a negative net margin of 290.14% and a negative trailing twelve-month return on equity of 38.53%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

(ZLAB) raised $100 million in an initial public offering on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO.

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

Zai Lab's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (3.48%), Credit Suisse AG (3.11%), Segantii Capital Management Ltd (2.29%), Genesis Investment Management LLP (1.64%), Price T Rowe Associates Inc. MD (1.50%) and State Street Corp (1.49%). Insiders that own company stock include Harald Reinhart, John D Diekman, John D Diekman, Kai-Xian Chen, Peter Wirth, Tao Fu, William Ki Chul Cho, William Lis and Ying Du.
View institutional ownership trends.

Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ZLAB stock can currently be purchased for approximately $38.92.

Zai Lab (NASDAQ:ZLAB) has a market capitalization of $3.81 billion and generates $144.31 million in revenue each year. The company earns $-704,470,000.00 in net income (profit) each year or ($5.55) on an earnings per share basis.

The company employs 1,951 workers across the globe.

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The official website for the company is www.zailaboratory.com. The company can be reached via phone at 862161632588, via email at jsteier@burnsmc.com, or via fax at 86-21-6163-2570.